ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Development and validation of nomograms to predict brain metastasis-free survival in lung and breast cancer.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary lung cancer (LC) and breast cancer (BC) are among the most common malignancies and are highly prone to brain metastasis (BM). This study aimed to identify risk factors for brain metastasis-free survival in patients with primary LC or BC and to construct clinically simple nomograms. Our study analyzed the independent factors for the occurrence of BM by univariate and multivariate Cox regression based on the training set and then developed nomograms. The performance of the nomogram was determined by the C-index and calibration curve. The results were verified with a validation set. A total of 1739 patients with primary LC and 1150 with primary BC were included in our retrospective study. In primary LC, pathological staging, N stage, targeted therapy, and chemotherapy treatment were significantly associated with BM. In primary BC, the factors significantly associated with BM were TNBC, Ki-67 index, targeted therapy, radiotherapy, and surgery. These two nomograms had discriminatory ability, with C-indices of 0.786 and 0.783 in the training set and 0.809 and 0.843 in the validation set, respectively. We constructed and validated predictive nomograms for the development of BM in patients with primary LC or BC. The proposed nomograms certainly have good performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.